We've found
6,570 Prostate Cancer
clinical trials
We've found
6,570 Prostate Cancer
clinical trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Urothelial Carcinoma Clinical Trial
Updated: 8/16/2016
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Enrolling,
Phase
IV
Updated: 8/16/2016
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 2/7/2018
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Status: Enrolling,
Phase
I, II
Updated: 2/7/2018
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 2/7/2018
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Status: Enrolling,
Phase
I, II
Updated: 2/7/2018
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 2/7/2018
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Status: Enrolling,
Phase
I, II
Updated: 2/7/2018
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Safety Study of MGD009 in B7-H3-expressing Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 4/1/2016
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Status: Enrolling,
Phase
IV
Updated: 4/1/2016
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 4/1/2016
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Status: Enrolling,
Phase
IV
Updated: 4/1/2016
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 4/1/2016
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Status: Enrolling,
Phase
IV
Updated: 4/1/2016
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 4/1/2016
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Status: Enrolling,
Phase
IV
Updated: 4/1/2016
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

UC (Urothelial Cancer) Clinical Trial
Updated: 12/31/1969
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

UC (Urothelial Cancer) Clinical Trial
Updated: 12/31/1969
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 12/31/1969
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 12/31/1969
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 12/31/1969
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 12/31/1969
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Castration Resistant Prostate Cancer Clinical Trial
Updated: 12/31/1969
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
